Nucor earnings beat by $0.08, revenue fell short of estimates
Investing.com - Wells Fargo (NYSE:WFC) raised its price target on Boston Scientific (NYSE:BSX) to $124.00 from $118.00 on Thursday, while maintaining an Overweight rating on the medical device maker’s stock. The stock, currently trading at $107.76, sits near its 52-week high of $108.94, having delivered a strong year-to-date return of 20.64%. According to InvestingPro analysis, the stock appears overvalued at current levels.
The company reported second-quarter sales of $5.06 billion, representing 17.4% organic growth, exceeding analyst expectations of $4.9 billion. The strong performance was driven by significant momentum in the company’s Pulse Field Ablation (PFA) technology, with U.S. electrophysiology growth reaching 117% year-over-year, and increased adoption of its Watchman device. InvestingPro data shows Boston Scientific maintains a GREAT financial health score, with revenue growth of 19.36% over the last twelve months.
Boston Scientific raised its 2025 organic growth guidance to 14-15% from the previous 12-14%, and increased its earnings per share guidance to $2.95-2.99, ahead of the consensus estimate of $2.92. The company now expects operating margin expansion of 75-100 basis points year-over-year, up from its prior forecast of 50-75 basis points. With a market capitalization of $159.43 billion and a P/E ratio of 61.4x, investors seeking deeper insights can access comprehensive valuation metrics and 15+ additional ProTips through InvestingPro.
For the third quarter, Boston Scientific guided for organic sales growth of 12-14% and earnings per share of $0.70-0.72. The company noted that China, representing approximately 7% of sales, grew in the mid-teens driven by Farapulse and IVUS launches, while Japan saw high teens growth from Farapulse new account openings.
Wells Fargo’s new price target is based on 37 times its 2026 earnings per share forecast for Boston Scientific, with the analyst noting that the company believes the Left Atrial Appendage Closure (LAAC) category can grow at a rate exceeding 20%.
In other recent news, Boston Scientific reported its second-quarter 2025 earnings, surpassing analysts’ expectations. The company achieved an adjusted earnings per share (EPS) of $0.75, which was higher than the forecasted $0.73. Additionally, Boston Scientific reported revenue of $5.06 billion, exceeding the anticipated $4.89 billion. In light of these financial results, BofA Securities has raised its price target for Boston Scientific to $120 from $115, while maintaining a Buy rating. Analyst Travis Steed from BofA Securities noted a $100 million impact on the adjusted income statement in his analysis. These developments highlight the company’s strong financial performance and positive reception from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.